Brexit - The Consequences for Pharmaceutical Patents and Supplementary Protection Certificates
Now that the UK has left the EU, and the transition period following this departure is over, we have a clearer view on the implications of Brexit on intellectual property rights and the consequences for UK based pharmaceutical companies. Although little has changed for UK applicants wishing to obtai...
Saved in:
Main Authors: | Harry Melville O'Brien (Author), Anna Louise Hatt (Author), James Alexander Stones (Author) |
---|---|
Format: | Book |
Published: |
University of Huddersfield Press,
2021-05-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Brexit - What are the potential consequences for pharma patents and SPCs
by: Jamie Fraser, et al.
Published: (2017) -
Case Law: A Review of Selected Pharmaceutical Patents in the UK Courts During 2020
by: Sarah-Jane Crawford, et al.
Published: (2021) -
Case Law: A Review of Selected Pharmaceutical Patents in the UK Courts during 2021
by: Sarah-Jane Crawford, et al.
Published: (2022) -
Evaluating the impact of Brexit on the pharmaceutical industry
by: Fawz Kazzazi, et al.
Published: (2017) -
Supplementary protection certificates and their impact on access to medicines in Europe: case studies of sofosbuvir, trastuzumab and imatinib
by: Yuanqiong Hu, et al.
Published: (2020)